Clinical Trial Update: Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating everolimus and bevacizumab in advanced non-clear cell renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-01